BL Pharmtech Balance Sheet Health
Financial Health criteria checks 5/6
BL Pharmtech has a total shareholder equity of ₩30.6B and total debt of ₩4.0B, which brings its debt-to-equity ratio to 12.9%. Its total assets and total liabilities are ₩42.1B and ₩11.5B respectively.
Key information
12.9%
Debt to equity ratio
₩3.95b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩4.75b |
| Equity | ₩30.59b |
| Total liabilities | ₩11.47b |
| Total assets | ₩42.06b |
Recent financial health updates
BL Pharmtech (KOSDAQ:065170) Has Debt But No Earnings; Should You Worry?
Sep 03
Is BL Pharmtech (KOSDAQ:065170) A Risky Investment?
Mar 07Does Next Bt (KOSDAQ:065170) Have A Healthy Balance Sheet?
Jan 20
Recent updates
BL Pharmtech (KOSDAQ:065170) Has Debt But No Earnings; Should You Worry?
Sep 03Some Confidence Is Lacking In BL Pharmtech Corp.'s (KOSDAQ:065170) P/S
May 21Is BL Pharmtech (KOSDAQ:065170) A Risky Investment?
Mar 07Reflecting on Next Bt's (KOSDAQ:065170) Share Price Returns Over The Last Three Years
Mar 14Does Next Bt (KOSDAQ:065170) Have A Healthy Balance Sheet?
Jan 20Next Bt's (KOSDAQ:065170) Shareholders Are Down 43% On Their Shares
Nov 28Financial Position Analysis
Short Term Liabilities: A065170's short term assets (₩7.5B) exceed its short term liabilities (₩6.6B).
Long Term Liabilities: A065170's short term assets (₩7.5B) exceed its long term liabilities (₩4.8B).
Debt to Equity History and Analysis
Debt Level: A065170 has more cash than its total debt.
Reducing Debt: A065170's debt to equity ratio has reduced from 26.8% to 12.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A065170 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if A065170 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.